February 01, 2013 at 11:31 AM EST
Hyperion's (HPTX) Ravicti Wins FDA Approval To Treat UCDs
Hyperion Therapeutics Inc.'s (NASDAQ: HPTX) new drug to treat urea cycle disorders (UCDs) has won approval from the U.S. health regulators. The U.S. Food and Drug Administration (FDA) cleared Ravicti (glycerol phenylbutyrate) for the chronic management of some UCDs in patients ages 2 years and older. [More...]
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here